Bayer Sues J&J Over False Prostate Cancer Drug Ads

Bayer Challenges J&J's Drug Efficacy Claims in Lawsuit

Bayer AG has initiated legal action against Johnson & Johnson, accusing the company of disseminating false and misleading advertisements for its prostate cancer drug, Erleada. The lawsuit alleges these claims unfairly damage the market position of Bayer’s competing drug, Nubeqa.

Overview of the Dispute

The core of the lawsuit is a Johnson & Johnson advertising campaign claiming Erleada reduces the risk of death by 51% compared to Nubeqa. Bayer contends this claim is based on a retrospective observational study, not a randomized controlled clinical trial, which is the standard for such comparisons. The complaint highlights that Nubeqa was used off-label for most of the study period, creating a fundamental non-comparability between patient groups.

Market and Financial Implications

Both Nubeqa and Erleada are key treatments in the lucrative market for metastatic castration-sensitive prostate cancer. In the first nine months of 2025, Bayer reported Nubeqa sales of €1.63 billion. The lawsuit seeks to compel Johnson & Johnson to correct its marketing claims, which could significantly impact future sales and market share for both pharmaceutical giants.

Conclusion and Outlook

The court's decision will be critical in defining advertising standards for prescription drugs based on real-world data. The outcome could set a precedent for how pharmaceutical companies use non-clinical trial data in competitive marketing. Investors will be closely watching for any impact on stock performance.

FAQ

Q: Why is Bayer suing Johnson & Johnson?
A: Bayer alleges that Johnson & Johnson made false and misleading claims in advertisements for its prostate cancer drug Erleada, negatively affecting sales of Bayer's competing drug, Nubeqa.

Q: What is the basis for Johnson & Johnson's advertising claim?
A: The claim of superior efficacy is based on a retrospective analysis of real-world data, which Bayer argues is not a valid substitute for a randomized controlled clinical trial.

Source: Investing.com